Disposition of 22337 shares by Lucera Erick of Editas Medicine at 5.6142 subject to Rule 16b-3
| EDIT Stock | USD 2.44 0.07 2.95% |
Slightly above 56% of all Editas Medicine's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Editas Medicine suggests that some traders are interested. Editas Medicine's investing sentiment can be driven by a variety of factors including economic data, Editas Medicine's earnings reports, geopolitical events, and overall market trends.
Editas |
Filed transaction by Editas Medicine Officer: Evp, Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Editas Medicine Fundamental Analysis
We analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Editas Medicine is currently under evaluation in target price category among its peers.
Editas Medicine Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Editas Medicine stock to make a market-neutral strategy. Peer analysis of Editas Medicine could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics with similar companies.
Peers
Editas Medicine Related Equities
| SANA | Sana Biotechnology | 11.06 | ||||
| DNA | Ginkgo Bioworks | 8.95 | ||||
| PRME | Prime Medicine, | 7.74 | ||||
| BEAM | Beam Therapeutics | 6.23 | ||||
| VERV | Verve Therapeutics | 5.43 | ||||
| ALLO | Allogene Therapeutics | 4.74 | ||||
| NTLA | Intellia Therapeutics | 3.62 | ||||
| CRSP | Crispr Therapeutics | 3.43 | ||||
| CRBU | Caribou Biosciences | 2.02 | ||||
| VRTX | Vertex Pharmaceuticals | 0.13 |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.